These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35338048)

  • 1. Metabolic dysfunction-related liver disease as a risk factor for cancer.
    Taylor A; Siddiqui MK; Ambery P; Armisen J; Challis BG; Haefliger C; Pearson ER; Doney ASF; Dillon JF; Palmer CNA
    BMJ Open Gastroenterol; 2022 Mar; 9(1):. PubMed ID: 35338048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus.
    Li WD; Fu KF; Li GM; Lian YS; Ren AM; Chen YJ; Xia JR
    World J Gastroenterol; 2015 Aug; 21(32):9607-13. PubMed ID: 26327768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
    Chakrabarty M; Jha AN; Sharma DJ
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
    Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
    PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-dependent effects of diabetes and obesity on liver-related events in non-alcoholic fatty liver disease: Subanalysis of CLIONE in Asia.
    Seko Y; Kawanaka M; Fujii H; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Morishita A; Munekage K; Kawata K; Yamamura S; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Okanoue T; Itoh Y; Nakajima A;
    J Gastroenterol Hepatol; 2022 Dec; 37(12):2313-2320. PubMed ID: 36198983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.
    Ampuero J; Aller R; Gallego-Durán R; Crespo J; Calleja JL; García-Monzón C; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Albillos A; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Guerra MH; Augustín S; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero Gómez M;
    J Hepatol; 2020 Jul; 73(1):17-25. PubMed ID: 32147361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: A population-based cohort study.
    Zhu L; Jiang J; Zhai X; Baecker A; Peng H; Qian J; Zhou M; Song C; Zhou Y; Xu J; Liu H; Hang D; Hu Z; Shen H; Zhang ZF; Zhu F
    Liver Int; 2019 Jan; 39(1):70-80. PubMed ID: 30025200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
    Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
    Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
    Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
    Portillo-Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K
    J Clin Endocrinol Metab; 2015 Jun; 100(6):2231-8. PubMed ID: 25885947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
    Younossi ZM; Golabi P; de Avila L; Paik JM; Srishord M; Fukui N; Qiu Y; Burns L; Afendy A; Nader F
    J Hepatol; 2019 Oct; 71(4):793-801. PubMed ID: 31279902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated detection of non-alcoholic fatty liver disease increases the incidence risk of type 2 diabetes in young adults.
    Kim JH; Lyu YS; Kim MK; Kim SY; Baek KH; Song KH; Han K; Kwon HS
    Diabetes Obes Metab; 2024 Jan; 26(1):180-190. PubMed ID: 37872007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence over time and regression of nonalcoholic fatty liver disease in type 2 diabetes.
    Giorda C; Forlani G; Manti R; Mazzella N; De Cosmo S; Rossi MC; Nicolucci A; Russo G; Di Bartolo P; Ceriello A; Guida P;
    Diabetes Metab Res Rev; 2017 May; 33(4):. PubMed ID: 28032449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future health and economic burden of obesity-attributable type 2 diabetes and liver disease among the working-age population in Saudi Arabia.
    Coker T; Saxton J; Retat L; Alswat K; Alghnam S; Al-Raddadi RM; Abdul Razack HI; Webber L; Alqahtani SA
    PLoS One; 2022; 17(7):e0271108. PubMed ID: 35834577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 17. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Non-alcoholic steatohepatitis (NASH) : a model of metabolic inflammation («metaflammation»)].
    Scheen AJ; Luyckx FH; Esser N; Lamproye A; Delwaide J; Paquot N
    Rev Med Liege; 2022 May; 77(5-6):316-322. PubMed ID: 35657189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of NAFLD With Diabetes and the Impact of BMI Changes: A 5-Year Cohort Study Based on 18,507 Elderly.
    Liu M; Wang J; Zeng J; Cao X; He Y
    J Clin Endocrinol Metab; 2017 Apr; 102(4):1309-1316. PubMed ID: 28324002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.